Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Long-term Follow-up of Metaphyseal Sclerotic Lines in Children Treated with Pamidronate

파미드로네이트 치료받은 환자에서 발생한 골간단 경화성 선에 대한 장기간 추적 연구

  • Choi, Yu-Mi (Theall Medibio Research Institute) ;
  • Suh, Jin-Soon (Department of Pediatrics, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea) ;
  • Cho, Byoung-Soo (Theall Medibio Research Institute)
  • 최유미 (디올 신장센터) ;
  • 서진순 (가톨릭의대 부천성모병원 소아청소년과) ;
  • 조병수 (디올 신장센터)
  • Received : 2014.06.05
  • Accepted : 2014.09.25
  • Published : 2014.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Bisphosphonates are widely used for the management steroid-induced osteoporosis (SIO) in children. With the increasing use of bisphosphonates, there have been reports of abnormal radiological findings in the growing skeleton. Therefore, their use in pediatric patients remains controversial. The present study was conducted to evaluate the long-term follow-up radiographic features, particularly metaphyseal sclerotic lines, in children who receive pamidronate therapy for nephropathy. Methods: Twenty-four children with nephropathy treated with oral calcium and pamidronate (mean duration, 9 months; dose, 100 mg daily), were evaluated retrospectively. All patients had SIO secondary to chronic glucocorticoid therapy for treating nephropathy. Long bone radiographic imaging was performed before treatment with pamidronate, and at follow-up, several years later. Physeal growth rates were estimated by measuring the distance that the sclerotic lines moved on the radiographs during the corresponding time intervals. Results: The mean follow-up period was 138 months. Long bone radiographs showed well-defined sclerotic lines at the metaphyseal ends, progressively moving from the physeal plate to the diaphysis, in all patients. The mean rate of movement of the sclerotic line was 6.21 mm per year. In 12 patients, the lines disappeared. The mean rate of growth in height was 7.33 cm per year. Conclusions: Results of long-term follow-up suggest that the metaphyseal sclerotic lines associated with pamidronate treatment tend to disappear without affecting overall skeletal growth. Bisphosphonate treatment for SIO in children with nephropathy seems to be safe, although further studies in larger number of patients are needed.

목적: 비스포스포네이트는 스테로이드 유발성 골다공증을 앓고 있는 환자의 치료에 널리 사용되어 왔다. 비스포스포네이트의 사용이 증가되면서 성장 중인 뼈에서 보이는 방사선학적 이상 소견에 대한 몇몇 보고가 있었다. 그래서 소아 환자에서 비스포스포네이트를 사용하는 것에 대해서는 논란의 여지가 있다. 이번 연구는 신병증을 가진 소아 환자에서 파미드로네이트 치료를 했을 때 발생한 방사선학적 이상 소견, 특히 골간단 경화성 선을 장기간 추적 관찰한 결과를 알기 위한 것이다. 방법: 경구로 칼슘제와 파미드로네이트(용량: 매일 100 mg)를 복용한 24명의 신병증 환아(평균 복용 기간: 9개월)를 후향적으로 연구하였다. 모든 대상 환아는 신병증에 대한 치료로 장기간 스테로이드 치료를 받았기 때문에 스테로이드 유발성 골다공증을 앓고 있었다. 파미드로네이트 치료 전에 장골의 방사선 사진을 촬영하였으며 수년간 추적 관찰 하였다. 뼈의 성장 속도는 검사를 시행한 시간 간격에 따라 방사선 사진 상에서 경화성 선이 이동한 거리를 측정하여 계산하였다. 결과: 평균 추적 관찰 기간은 138개월이었다. 장골의 방사선 사진 상, 모든 환자에서 골간단의 끝부분에서 뚜렷한 경화성 선이 관찰 되었으며 이 경화성 선은 성장판에서 골간쪽으로 점점 이동하였다 경화성 선의 평균 이동 속도는 6.21 mm/년이었다. 24명 중 12명의 환자에서는 경화성선이 완전히 사라졌다. 그리고 평균 키의 성장 속도는 7.33 cm/년이었다. 결론: 이번 연구에서 장기간 동안 추적 관찰한 결과 파미드로네이트 치료와 연관된 골간단부의 경화성 선은 뼈 성장에 영향을 주지 않았으며 점점 없어지는 경향을 보였다. 그러므로 신병증을 가진 소아 환자에서 스테로이드 유발성 골다공증을 비스포스포네이트로 치료하는 것은 안전한 것으로 생각된다. 그러나 좀 더 많은 수의 환자를 대상으로 하는 추가적인 연구가 필요하다.

Keywords

References

  1. Al Muderis M, Azzopardi T, Cundy P. Zebra lines of pamidronate therapy in children. J Bone Joint Surg Am 2007;89:1511-6. https://doi.org/10.2106/JBJS.F.00726
  2. Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003;33:226-9. https://doi.org/10.1007/s00247-003-0865-1
  3. Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 2004;19:1191-3. https://doi.org/10.1359/JBMR.040303
  4. Kim SD, Cho BS. Pamidronate therapy for preventing steroid-induced osteoporosis in children with nephropathy. Nephron Clin Pract 2006;102:c81-7. https://doi.org/10.1159/000089664
  5. Onwuneme C, Abdalla K, Cassidy N, Hensey O, Ryan S. Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis. Arch Dis Child 2007;92:1087. https://doi.org/10.1136/adc.2007.129692
  6. Suresh S, Thomas JK. Metaphyseal bands in osteogenesis imperfect. Indian J Radiol Imaging 2010;20:42-4. https://doi.org/10.4103/0971-3026.59752
  7. Hong IK, Suh JS, Lee YA, Kim DY. Scintigraphic findings of growth arrest lines after bisphosphonate administration in a steroid-induced osteoporosis patient: a case study. Clin Nucl Med 2010;35:740-2. https://doi.org/10.1097/RLU.0b013e3181ea3448
  8. Devogelaer JP, Malghem J, Maldaque B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987;16:360-3. https://doi.org/10.1007/BF00350961
  9. Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics 1994;94:385-9.
  10. Ogden JA. Growth slowdown and arrest lines. J Pediatr Orthop 1984;4:409-15. https://doi.org/10.1097/01241398-198408000-00003
  11. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, et al. International Society for Clinical Densitometry: Official positions of the International Society for Clinical Densitometry. J Clin endocrinol Metab 2004;89:3651-5. https://doi.org/10.1210/jc.2004-0124
  12. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997;76:266-83. https://doi.org/10.1097/00005792-199707000-00005
  13. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 1998;157:261-2.
  14. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001;14:529-33.
  15. Sumnik Z, Land C, Rieger-Wettengi G, Korber F, Strabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res 2004;61:137-42. https://doi.org/10.1159/000075589
  16. Barros ER, Dias da Silva MR, Kunii IS, Lazaretti-Castro M. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab 2008;21:811-8.
  17. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52. https://doi.org/10.1056/NEJM199810013391402
  18. Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005;18:43-53.
  19. Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta-- lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002;15:163-74.
  20. Silverman SL, Hurvitz EA, Nelson VS, Chiodo A. Rachitic syndrome after disodium etidronate therapy in an adolescent. Arch Phys Med Rehabil 1994;75:118-20.